Study to investigate safety, tolerability and PK following single and multiple ascending doses of AZD7295 in Japanese
Study identifier:D1820C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Randomized, Double-Blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7295 following Single and Multiple Ascending Oral Dose Administration in Healthy Male Japanese Subjects
Medical condition
Healthy subjects
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD7295, Placebo
Sex
Male
Actual Enrollment
62
Study type
Interventional
Age
20 Years - 55 Years
Date
Study Start Date: 01 Dec 2008
Primary Completion Date: -
Study Completion Date: 01 May 2009
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD7295 ascending single doses (start dose 90 mg), oral solution and then multiple ascending dose (tbd based on single dose results), oral solution |
| Placebo Comparator: 2 | Drug: Placebo multiple ascending dose (tbd based on single dose results), oral solution |
Contacts
Investigators
Principal Investigator
Masatoshi Tsukamoto
Kyushu Clinical Pharmacolgy Reasearch Clinic
